Nomura retained a Buy rating for Gland Pharma Ltd, citing its pivot to a CDMO model.
1 report, 1 independent
Updated Oct 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Nomura retained a Buy rating for Gland Pharma Ltd, citing its pivot to a CDMO model.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Nomura
corporation in Japan
Nothing else this week.
Related events
- Nomura maintained a 'Buy' rating on India's most valuable company.
- Nomura maintained a neutral rating on Bank of Baroda shares.
- Nomura maintained a 'Reduce' call on Meesho shares, while Motilal Oswal maintained a 'Buy' rating.
- Nomura maintained a 'Buy' rating on Ambuja Cements, citing operational challenges and cost pressures.
- Nomura provided financial analysis regarding Nasdaq options.